NVAX Jan 2025 17.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:38PM EDT. Market open.
| Previous Close | 0.7200 |
| Open | 0.1500 |
| Bid | 2.4100 |
| Ask | 2.8000 |
| Strike | 17.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 1.0000 - 2.9900 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.75k |
ZacksNovavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
Insider MonkeyNovavax, Inc. (NASDAQ:NVAX) Q1 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q1 2024 Earnings Call Transcript May 12, 2024 Novavax, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Novavax’ First Quarter 2024 Financial Results and Operational Highlights Conference Call. All lines will […]
- GuruFocus.com
Novavax Inc (NVAX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Partnerships and ...
Discover how Novavax Inc (NVAX) is reshaping its future with significant Sanofi collaboration and revised financial projections in Q1 2024.
© 2024 Yahoo. All rights reserved.